Optimizing Oncology Trials with a ctDNA Test Custom-Built for MRD and Molecular Monitoring

Join this webinar to discover the advantages of using Signatura™ (RUO), a novel assay custom-designed for each patient that detects circulating tumour DNA (ctDNA) with high sensitivity and specificity to monitor molecular residual disease, early recurrence, and treatment response across solid tumours. Learn about the latest clinical data for Signatura and explore how this unique ctDNA assay can be applied in pharmaceutical development and oncology clinical study design, potentially increasing the probability of trial success, reduce the time to trial readout, and decrease clinical trial costs
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Accelerate your Drug Development process with Lonza Engine™

Pharmtech

Speed and quality are key in pharmaceutical manufacturing. How can your equipment add value to your production process? Join the Lonza team to discover how the new Lonza Engine™ equipment portfolio is designed to support bioavailability enhancement, encapsulation and early-phase clinical development technologies.
Watch Now

INTERNATIONAL WEBINAR ON PHARMACY AND PHARMA NETWORKS

Pharma Webinar 2022 welcomes all participants throughout the world to attend the International Webinar on Pharmacy and Pharma networks will be held during April 18-19, 2022.
Watch Now

Regulatory Strategies for the Analytical Development of New Biological Entities and Biosimilars

xtalks

The webinar will focus on the relationship between analytics of biotherapeutic products and the interpretation of data to build and support a solid regulatory Chemistry, Manufacturing and Control (CMC) strategy. The importance of data interpretation is illustrated in the development of biosimilars and new biological entities, as well as in regulatory specifications regarding biotherapeutic products.
Watch Now

The 2nd Life Sciences Sector Deal and the NHS 10 Year Plan

pharmaphorum

Brexit uncertainty isn’t going away any time soon – but it’s important to remember that the UK government has already set out two plans for the future shape of the country’s healthcare industry: the second Life Sciences Sector Deal and the long-term plan for the NHS. With these two plans in place there are plenty of opportunities for the industry and the government to work together to keep the UK at the top of the international life sciences sector – and perhaps reach even greater heights.
Watch Now

Spotlight

resources